Literature DB >> 25785345

A case of mixed adenoneuroendocrine carcinoma of the stomach with focal intestinal metaplasia and hypergastrinemia.

Hayato Yamauchi1, Shinji Sakurai, Nobuhiro Nakazawa, Tomonori Yoshida, Yuichi Tabe, Kana Saitoh, Takaharu Fukasawa, Shinsuke Kiriyama, Hiroshi Naitoh, Hiroyuki Kuwano.   

Abstract

Among neuroendocrine neoplasms, mixed exocrine and endocrine characteristics with at least 30% of each component are classified into mixed adenoneuroendocrine carcinoma (MANEC), according to the 2010 World Health Organization classification. We experienced a rare case of MANEC of the stomach with focal intestinal metaplasia and hypergastrinemia. A 76-year-old Japanese male was diagnosed as having gastric adenocarcinoma and underwent total gastrectomy. The pathologic diagnosis was MANEC of the stomach accompanied by unusual mucosal atrophy without Helicobacter pylori infection, the characteristics of which were different from both type A and type B atrophic gastritis. The patient has a history of long-term use of a proton pump inhibitor. Additional serum chemistry examination using preoperatively obtained plasma from the patient revealed hypergastrinemia. The mechanism of gastric MANEC carcinogenesis is still unclear, but that might be correlated with unusual intestinal metaplasia and hypergastrinemia in this case.

Entities:  

Keywords:  Hypergastrinemia; Intestinal metaplasia; Mixed adenoneuroendocrine carcinoma; Proton pump inhibitor; Stomach

Mesh:

Substances:

Year:  2015        PMID: 25785345      PMCID: PMC4370553          DOI: 10.9738/INTSURG-D-14-00074.1

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  29 in total

Review 1.  Gastritis.

Authors:  R G Strickland
Journal:  Springer Semin Immunopathol       Date:  1990

2.  Signet ring cells in gastric carcinomas are derived from neuroendocrine cells.

Authors:  Karin Bakkelund; Reidar Fossmark; Ivar Nordrum; Helge Waldum
Journal:  J Histochem Cytochem       Date:  2005-12-12       Impact factor: 2.479

Review 3.  Review article: Pathogenesis and management of gastric carcinoid tumours.

Authors:  M D Burkitt; D M Pritchard
Journal:  Aliment Pharmacol Ther       Date:  2006-11-01       Impact factor: 8.171

Review 4.  Current pharmacotherapy options for gastritis.

Authors:  Wouter J den Hollander; Ernst J Kuipers
Journal:  Expert Opin Pharmacother       Date:  2012-11-20       Impact factor: 3.889

5.  Differential proteomics of Helicobacter pylori associated with autoimmune atrophic gastritis.

Authors:  Ombretta Repetto; Stefania Zanussi; Mariateresa Casarotto; Vincenzo Canzonieri; Paolo De Paoli; Renato Cannizzaro; Valli De Re
Journal:  Mol Med       Date:  2014-02-28       Impact factor: 6.354

Review 6.  Safety profile of Lansoprazole: the US clinical trial experience.

Authors:  J W Freston; P A Rose; C A Heller; M Haber; D Jennings
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

7.  Concurrent occurrence of adenocarcinoma and carcinoid tumor in the stomach: a composite tumor or collision tumors?

Authors:  M Yamashina; R A Flinner
Journal:  Am J Clin Pathol       Date:  1985-02       Impact factor: 2.493

8.  Multifocal early gastric cancer in a patient with autoimmune atrophic gastritis and iron deficiency anaemia.

Authors:  A Neesse; P Michl; P Barth; M Vieth; P Langer; V Ellenrieder; T M Gress
Journal:  Z Gastroenterol       Date:  2009-02-05       Impact factor: 2.000

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update.

Authors:  Stefano La Rosa; Alessandro Marando; Fausto Sessa; Carlo Capella
Journal:  Cancers (Basel)       Date:  2012-01-16       Impact factor: 6.639

View more
  6 in total

1.  Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy.

Authors:  Hajime Anjiki; Ken-Ichi Mukaisho; Yu Kadomoto; Hisakazu Doi; Kunio Yoshikawa; Takahisa Nakayama; Diem Thi-Ngoc Vo; Takanori Hattori; Hiroyuki Sugihara
Journal:  Clin J Gastroenterol       Date:  2017-02-03

Review 2.  Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift.

Authors:  Helge L Waldum; Kjell Öberg; Øystein F Sørdal; Arne K Sandvik; Bjørn I Gustafsson; Patricia Mjønes; Reidar Fossmark
Journal:  Therap Adv Gastroenterol       Date:  2018-05-27       Impact factor: 4.409

3.  Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report.

Authors:  Zhixian Lin; Jiangfeng Chen; Yong Guo
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

4.  Clinical characteristics of early neuroendocrine carcinoma in stomach: A case report and review of literature.

Authors:  Xiaolong Zhu; Haiyan Jing; Takashi Yao
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

5.  A case of mixed adenoneuroendocrine carcinoma (MANEC) arising in Barrett's esophagus: literature and review.

Authors:  Tetsuro Kawazoe; Hiroshi Saeki; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudou; Ryota Nakanishi; Nobuhide Kubo; Koji Ando; Yuichiro Nakashima; Eiji Oki; Minako Fujiwara; Yoshinao Oda; Yoshihiko Maehara
Journal:  Surg Case Rep       Date:  2018-05-08

6.  Endoscopic findings of gastric mixed adenoneuroendocrine carcinoma: A case report.

Authors:  Keitaro Takahashi; Mikihiro Fujiya; Takahiro Sasaki; Yuya Sugiyama; Yuki Murakami; Takuya Iwama; Takehito Kunogi; Katsuyoshi Ando; Nobuhiro Ueno; Shin Kashima; Kentaro Moriichi; Hiroki Tanabe; Sayaka Yuzawa; Hidehiro Takei; Toshikatsu Okumura
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.